Recent 8-K filings for HSDT
Highest-materiality recent filing
HSDT closes >$500M private placement to launch SOL treasury; appoints Joseph Chee as Executive Chairman
- Raised $508.7M gross proceeds; potential total >$1.25B if all stapled warrants exercised at $10.134.
- Net proceeds to acquire SOL as primary treasury reserve asset; plans to scale holdings over 12-24 months.
-
Solana increases ATM offering capacity from $92.8M to $250.0M via amended sales agreement
Amended Sales Agreement with Clear Street and Maxim raises max aggregate gross proceeds from $92.8M to $250.0M.
-
Solana Company Q1 revenue $3.6M, net loss $99.8M ($1.30/share) on digital asset write-downs
Q1 revenue $3.6M (primarily $3.4M staking rewards) vs $49K in Q1 2025; gross profit $3.4M.
-
HSDT raises $8M in registered direct offering; puts offer 7% IRR repurchase
Issued 3,076,922 shares at $2.60/share; net proceeds ~$7.9M.
-
Solana Company CMO Antonella Favit-Van Pelt departs with $875,000 separation payment
Dr. Favit-Van Pelt resigned as Chief Medical Officer effective April 8, 2026, under a mutual separation agreement.
-
Solana Q4 net income $325.6M ($4.25 EPS) on $5.2M revenue; $293.7M in SOL holdings
Q4 2025 revenue $5.2M (vs $0.2M prior year), driven by $5.1M staking rewards.
-
Solana (HSDT) Q3 net loss $352.8M; $500M+ SOL treasury partnership closed
Q3 net loss $352.8M ($32.89 loss per share) vs $3.7M loss a year ago; operating loss $35.5M vs $4.1M.
-
Solana Company OKs $100M share buyback; board changes announced
Board authorized $100M stock repurchase program; open-ended, open market & negotiated transactions.
-
Solana Company elects Pantera Capital's Cosmo Jiang to Board; highlights Solana network growth
Elected Cosmo Jiang, General Partner at Pantera Capital, to the Board of Directors effective November 3, 2025.
-
Over 2.3M SOL held (increase of ~0.1M since Oct 6); cash/stablecoins exceed $15M.
-
Solana Company auditor switches from Baker Tilly to CBIZ; prior reports flagged going concern
Baker Tilly US, LLP resigned as independent auditor on October 15, 2025; Audit Committee accepted.
-
Helius Medical renames to Solana Company; signs LOI with Solana Foundation for SOL treasury strategy
Company name changed to Solana Company effective Sept 29, 2025; ticker HSDT unchanged.
-
FDA 510(k) filed for PoNS stroke label expansion under Breakthrough Device Designation.
-
Helius Medical starts SOL treasury; holds 760,190 tokens at avg cost $231
First acquisition of SOL tokens as part of digital asset treasury strategy; principal holding will be SOL.
-
Raised $508.7M gross proceeds; potential total >$1.25B if all stapled warrants exercised at $10.134.
-
Helius raises $500M+ in PIPE to fund SOL treasury; Joseph Chee named Executive Chairman
Offering priced at $6.881/share + stapled warrants at $10.134; gross proceeds ~$500M cash, up to $1.25B total.
-
Helius Medical enters ATM sales agreement for up to $92.8M; authorizes 800M shares
Entered Sales Agreement with Clear Street and Maxim to sell up to $92.8M of Class A common stock in at-the-market offerings.
-
Helius Medical reports positive PoNS Stroke Registrational Program results; FDA submission planned
Double-blind RCT met primary endpoint: statistically significant improvements in gait/balance with active PoNS therapy (with/without open-label data).
-
Helius Medical regains full Nasdaq compliance; subject to one-year monitor
Received Nasdaq notification on July 7, 2025 confirming compliance with $2.5M stockholders' equity requirement.
-
Helius Medical Technologies files prospectus for up to $25M at-the-market stock offering
Filed updated Prospectus Supplement for sale of up to $25M of common stock.
-
Helius regains Nasdaq equity compliance with $6.6M equity after $8.1M offering
Stockholders' equity of $6.561M as of June 17, 2025, above Nasdaq's $2.5M minimum.
-
Helius regains Nasdaq bid price compliance; equity rule deadline June 30, 2025 remains
Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) as of June 3, 2025.
-
Helius announces 1-for-15 reverse stock split effective May 1 to maintain Nasdaq listing
Reverse split approved by board at 1-for-15 ratio, effective 5:00 pm ET on May 1, 2025.
-
Helius Medical raises $1.3M via 20% OID notes and 1.32M shares in private placement
Aggregate principal of $1.56M in 20% original issue discount promissory notes; gross proceeds $1.3M before fees.
-
Shareholders approve reverse stock split and warrant inducement at annual meeting
Elected six directors: Blane Walter (1,001,991 for), Dane Andreeff, Edward Straw, Jeffrey Mathiesen, Paul Buckman, Sherrie Perkins.
-
Helius Medical gets Nasdaq delisting warning for equity <$2.5M; extension to June 30, 2025
Received Nasdaq notice on March 31, 2025 for stockholders' equity below $2.5M from FY2024 10-K.
-
Helius Medical faces Nasdaq delisting; to appeal, sets 2025 annual meeting for April 21
Received Nasdaq delisting notice on Feb 7, 2025 for continued bid price below $1; intends to appeal, hearing stays delisting.
-
Aggregate gross proceeds of ~$3.7M from cash exercise of 4,971,110 existing warrants at reduced price of $0.751/share.
-
CMS finalizes Medicare payment rates for Helius' PoNS Controller (A4593)
CMS posted final DMEPOS fee schedule payment rates for PoNS Controller (HCPCS A4593) on Jan 13, 2025.
-
Helius initiates strategic alternatives review after unfavorable CMS pricing for PoNS device
Engaged B. Riley Securities to advise on strategic alternatives including merger, sale, or licensing.
-
Revenue $182K vs $256K YoY due to PTAP termination; up 35% sequentially from Q1 2024.
-
Helius Medical receives Nasdaq delisting notice for bid price below $1.00 for 30 days
Nasdaq letter dated Aug 9, 2024; compliance period until Feb 5, 2025 to regain minimum bid price.
-
Helius Medical regains Nasdaq compliance with $2.5M equity rule after May 9 financing
Received formal Nasdaq notice on May 31, 2024 confirming compliance with Listing Rule 5550(b)(1).
-
Helius Medical Q1 rev $135K (+22% YoY); net loss flat $2.5M; CMS PoNS reimbursement milestone
Q1 revenue $135K vs $111K YoY; operating loss $3.4M vs $3.8M, driven by lower professional fees and clinical trial costs.
-
Helius Medical prices $6.4M public offering of stock and warrants
Offering consists of 804,999 shares, 2,047,222 pre-funded warrants, and Series A/B warrants for up to 5.7M shares.
-
CMS proposes preliminary Medicare payment rates for PoNS: mouthpiece $3,075.53, controller $1,206.53
CMS preliminary DMEPOS fee schedule sets PoNS Mouthpiece (A4594) capped payment at $3,075.53 based on cash pay price of $4,500.
-
Helius Medical receives Nasdaq delisting notice for failing minimum equity requirement
Stockholders' equity fell below $2.5M as of Dec 31, 2023, triggering Nasdaq Listing Rule 5550(b)(1) non-compliance.
-
Helius Medical Q4 revenue down 52% YoY; net loss per share $1.47 vs $8.66
Q4 2023 revenue $134K, down from $282K in Q4 2022, due to US PTAP expiration and lower Canada sales.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.65 · Most common event other_material